Open Philanthropy recommended a grant of $882,000 over two years to Georgia Tech to support a collaboration between Professor James Dahlman and Professor Jeffrey Glenn, of Stanford University, to develop and test novel lipid nanoparticles for use in antiviral drug candidates intended to prevent infections by all beta-coronaviruses and influenza strains. Effective pan-influenza and -coronavirus antiviral drugs could avert hundreds of thousands of deaths annually and minimize the spread of highly infectious and lethal strains of the viruses.
This falls within Open Philanthropy's work on scientific research, specifically within its interest in science supporting biosecurity and pandemic preparedness.